Predicting and preventing acute drug-induced liver injury: what's new in 2010?

Bibliography

• Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010;32(1):3-13
   PubMed Web of Science ®Google Scholar
• Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol 2010;26:222-6
   PubMed Web of Science ®Google Scholar
• Fontana RJ, editor. Advances in drug induced liver injury. Semin Liver Dis 2009;29:335-422
   PubMedGoogle Scholar
• Larrey D. Hepatotoxicity of drugs and chemicals. Gastroenterol Clin Biol 2009;33:1136-46
   PubMed Web of Science ®Google Scholar
• Assis DN, Navarro VJ. Human drug hepatotoxicity: a contemporary clinical perspective. Expert Opin Drug Metab Toxicol 2009;5:463-73
   PubMed Web of Science ®Google Scholar
• Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009;58:1555-64
   PubMed Web of Science ®Google Scholar
• Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol 2009;5:1-18
   PubMedGoogle Scholar
• Andrade RJ, Lucena MI, Fernandez C, Drug induced injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-21
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005;42:481-9
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-9
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury. Hepatology 2008;47:2003-9
   PubMed Web of Science ®Google Scholar
• Lammert C, Bjornsson E, Niklasson A, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010;51:615-20
   PubMed Web of Science ®Google Scholar
• Llanos L, Moreu R, Ortin T, Existence of a relationship between increased serum alanine aminotransferase levels (ALT) detected in premarketing clinical trials and postmarketing published hepatotoxicity case-reports. Aliment Pharmacol Ther 2010 Mar 13 (Epub) PMID: 20331578
   Google Scholar
• Chien JY, Huang RM, Wang JY, Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis 2010;14:616-21
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197:S279-93
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Agundez JA, Lucena MI, Pharmacogenomics in drug-induced liver injury. Curr Drug Metab 2009;10:956-70
   PubMed Web of Science ®Google Scholar
• Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010;243:154-66
   PubMed Web of Science ®Google Scholar
• Cui Y, Paules RS. Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenetics 2010;11:573-85
   Google Scholar
• Amacher DE. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 2010;245(1):134-42
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, Lahoz A, Gombau L, In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 2010;16(17):1963-77
   PubMed Web of Science ®Google Scholar
• Ozer JS, Chetty R, Kenna G, Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 2010;56:237-46
   PubMed Web of Science ®Google Scholar
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009;29:400-11
   PubMed Web of Science ®Google Scholar
• Daly AK, Donaldson PT, Bhatnagar P, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41(7):816-9
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Robles M, Ulzurrun E, Drug-induced liver injury: insights from genetic studies. Pharmacogenetics 2009;10:1467-87
   Google Scholar
• Mallal S, Phillips E, Carosi G, HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
   PubMed Web of Science ®Google Scholar
• Ozer JS, Ratner M, Shaw M, The current state of serum biomarkers of hepatoxicity. Toxicology 2008;245:194-205
   PubMed Web of Science ®Google Scholar
• Mattes WB, Walker EG. Translational toxicology and the work of the Predictive Safety Testing Consortium. Clin Pharmacol Ther 2009;85:327-30
   PubMed Web of Science ®Google Scholar
• Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests? Clin Pharmacol Ther 2009;85:331-4
   PubMed Web of Science ®Google Scholar
• Tragni E, Filippi A, Mazzaglia G, Monitoring statin safety in primary care. Pharmacoepidemiol Drug Saf 2007;16:652-7
   PubMed Web of Science ®Google Scholar
• Leaver H, Keng Lim T, Leaver J, Compliance to recommended liver function monitoring in patients on statins. Cardiovasc Ther 2009;27:96-100
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D, Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001;286:831-3
   PubMed Web of Science ®Google Scholar
• Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007;11:525-48
   PubMedGoogle Scholar
• Khalid SK, Lane J, Navarro V, Use of over-the-counter analgesics is not associated with acute decompensation in patients with cirrhosis. Clin Gastroenterol Hepatol 2009;7:994-9
   PubMed Web of Science ®Google Scholar
• Rossi S, Assis DN, Awsare M, Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf 2008;31:261-70
   PubMed Web of Science ®Google Scholar
• Hawkins LC, Edwards JN, Dargan PI. Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a review of the literature. Drug Saf 2007;30:465-79
   PubMed Web of Science ®Google Scholar
• Hawton K, Bergen H, Simkin S, Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis. BMJ 2009;338:b2270
   PubMed Web of Science ®Google Scholar
• Corcoran P, Reulbach U, Keeley HS, Use of analgesics in Intentional drug overdose presentations to hospital befote and alter the withdrawal of distalgesic from the Irish market. BMC Clin Pharmacol 2010;10(1):6
   PubMedGoogle Scholar
• Woodcock J. A difficult balance – pain management, drug safety, and the FDA. N Engl J Med 2009;361:2105-7
   PubMed Web of Science ®Google Scholar
• Ansari A, Elliott T, Baburajan B, Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:734-41
   PubMed Web of Science ®Google Scholar
• Sparrow MP, Hande SA, Friedman S, Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005;22:441-6
   PubMed Web of Science ®Google Scholar
• Lewis JH. Drug-induced liver disease. Med Clin North Am 2000;84(5):1275-11
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Watkins PB. Genetic predisposition to drug-induced liver disease. Gastroenetrol Clin North Am 1995;24(4):811-38
   PubMed Web of Science ®Google Scholar
• Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997;26(Suppl 2):12-21
   PubMedGoogle Scholar
• Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd edition. Lippincott Williams & Wilkins, Philadelphia; 1999
   Google Scholar
• Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008;28:175-87
   PubMed Web of Science ®Google Scholar
• Shapiro M, Lewis JH. Causality assessment of drug-induced liver disease. Promises and Pitfalls. Clin Liver Dis 2007;11:477-505
   PubMedGoogle Scholar
• Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008;28:1021-41
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Kastelein JJ, Poldermans D, Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007;23:1707-13
   PubMed Web of Science ®Google Scholar
• Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 2009;123:378-84
   PubMed Web of Science ®Google Scholar
• Wai CT, Tan BH, Chan CL. Drug-induced liver injury at an Asian center: a prospective study. Liver Int 2007;27:465-74
   PubMed Web of Science ®Google Scholar
• Lewis JH. “Hy's Law”, the “Rezulin Rule” and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006;15:221-9
   PubMed Web of Science ®Google Scholar
• Forget P, Wittebole X, Lattere PF. Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases. B J Anaesth 2009;103:899-900
   PubMed Web of Science ®Google Scholar
• Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272:1845-50
   PubMed Web of Science ®Google Scholar
• Maddox JF, Amuzie CJ, Li M, Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health 2010;73:58-73
   PubMed Web of Science ®Google Scholar
• Gandhi A, Guo T, Ghose R. Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. J Toxicol Sci 2010;35:163-73
   PubMed Web of Science ®Google Scholar
• Getachew Y, James L, Lee WM, Suceptibility to acetaminophen (APAP) toxicity unexpectedly is decreased during acute viral hepatitis in mice. Biochem Pharmacol 2010;79:1363-71
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yuen N, Walsh J, Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 2009;8:882-8
   Google Scholar
• Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol 2009;47:81-8
   PubMed Web of Science ®Google Scholar
• Andrews E, Armstrong M, Tugwood J, A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010;51(5):1656-64
   PubMed Web of Science ®Google Scholar
• Brinker AD, Wassel RT, Lyndly J, Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59:224-9
   PubMedGoogle Scholar
• Lee SW, Chung LS, Huang HH, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010;14:622-6
   PubMed Web of Science ®Google Scholar
• Sun F, Chen Y, Xiang Y, Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008;12:994-1002
   PubMed Web of Science ®Google Scholar
• Possuelo LG, Castelan JA, de Brito TC, Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673-81
   PubMed Web of Science ®Google Scholar
• Wang T, Wang W, Wang ZY, Association of P450-2E1 and GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity. Zhonghua Jie He He Hu Xi Za Zhi 2009;32:585-7
   PubMedGoogle Scholar
• Nader LA, de Mattos AA, Picon PD, Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann Hepatol 2010;9:70-4
   PubMed Web of Science ®Google Scholar
• de Castro L, do Brasil PE, Monteiro TP, Can hepatitis B virus infection predict tuberculosis treatment liver toxicity? Development of a preliminary prediction rule. Int J Tuberc Lung Dis 2010;14:332-40
   PubMed Web of Science ®Google Scholar
• Bliven EE, Podewils LJ. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection. Int J Tuberc Lung Dis 2009;13:1054-60
   PubMed Web of Science ®Google Scholar
• Orkin C, Wang J, Bergin C, An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. Pharmacogenet Genomics 2010;20:307-14
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007;21:41-6
   PubMed Web of Science ®Google Scholar
• Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010;85(1):190-200
   PubMed Web of Science ®Google Scholar
• Littera R, Carcassi C, Masala A, HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006;20:1621-6
   Google Scholar
• Gatanaga H, Yazaki H, Tanuma J, HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21(2):264-5
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197:S279-93
   PubMed Web of Science ®Google Scholar
• Hoffmann CJ, Charalambous S, Martin DJ, Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-85
   PubMed Web of Science ®Google Scholar
• Vispo E, Mena A, Maida I, Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7
   PubMed Web of Science ®Google Scholar
• Bruck S, Witte S, Brust J, Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008;13:343-8
   PubMed Web of Science ®Google Scholar
• Medrano J, Barreiro P, Tuma P, Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev 2008;10:110-5
   PubMed Web of Science ®Google Scholar
• Gao S, Gui XE, Deng L, Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. Hepatol Res 2010;40:287-94
   PubMed Web of Science ®Google Scholar
• Akhtar MA, Mathieson K, Arey B, Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol 2008;20:1194-204
   PubMed Web of Science ®Google Scholar
• Rubio A, Monpoux F, Huguon E, Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. J Pediatr Gastroenterol Nutr 2009;49:599-606
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Antinori A, Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009;37:244-9
   PubMed Web of Science ®Google Scholar
• McKoy JM, Bennett CL, Scheetz MH, Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf 2009;32:147-59
   PubMed Web of Science ®Google Scholar
• Kindmark A, Jawaid A, Harbron CG, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggest an underlying immune pathogenesis. Pharmacogenomics J 2007;15:1-10
   Google Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010;196:407-18
   PubMedGoogle Scholar
• Andersson U, Lindberg J, Wang S, A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 2009;14:572-86
   PubMed Web of Science ®Google Scholar
• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009;29:412-22
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63
   PubMed Web of Science ®Google Scholar
• Nelson A, Torres DM, Morgan AE, A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990-4
   PubMed Web of Science ®Google Scholar
• Zafra C, Abraldes JG, Turnes J, Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-55
   PubMed Web of Science ®Google Scholar
• Resch U, Tatzber F, Budinsky A, Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006; 61(3):262-74
   PubMed Web of Science ®Google Scholar
• Navarro V. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009;29(4):373-82
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing clinical evaluation. Available from: http://www.fda,gov/Drugs/ GuidanceCompliance RegulatoryInformation/ Guidances/default.htm [Accessed July 2009]
   Google Scholar
• Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009;13:1-9
   PubMed Web of Science ®Google Scholar
• Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009;15:2817-33
   PubMed Web of Science ®Google Scholar
• Hosomi H, Akai S, Minami K, An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. Toxicol In Vitro 2010;24:1032-8
   PubMed Web of Science ®Google Scholar
• McRae M, Rezk NL, Bridges AS, Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. Pharmacotherapy 2010;30:17-24
   PubMed Web of Science ®Google Scholar
• Winnike JH, Li Z, Wright FA, Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010;88:45-51
   PubMed Web of Science ®Google Scholar
• Adler M, Hoffman D, Ellinger-Ziegelbauer H, Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol Lett 2010;196:1-11
   PubMed Web of Science ®Google Scholar
• Available from: http://www.innomed-predtox.com/
   Google Scholar
• Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5:1023-38
   PubMed Web of Science ®Google Scholar
• Michna E, Duh MS, Korves C, Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med 2010;11:369-78
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services Food and Drug Administration. 21 CFR Part 201. [Docket No. FDA–1977–N–0013] (formerly Docket No. 1977N–0094L) RIN 0910–AF36. Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Overthe-Counter Human Use; Final Monograph AGENCY: Food and Drug Administration, HHS
   Google Scholar
• Bartels S, Sivilotti M, Crosby D, Are recommended doses of APAP hepatotoxic for recently abstinent alcoholics? A randomized trial. Clin Toxicol 2008;46:243-9
   PubMed Web of Science ®Google Scholar
• Kuffner EK, Green JL, Bogdan GM, The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study. BMC Med 2007;5:13
   PubMed Web of Science ®Google Scholar
• Lalonde RG, Thomas R, Rachlis A, Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Tissue Antigens 2010;75:12-8
   PubMed Web of Science ®Google Scholar
• Nieves Calatrava D, Calle-Martin OD, Iribarren-Loyarte JA, Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin 2010. [Epub ahead of print]
   Google Scholar
• Watson ME, Patel LG, Ha B, A study of HIV provider attitudes toward HLA-B 5701 testing in the United States. AIDS Patient Care STDS 2009;23:957-63
   PubMed Web of Science ®Google Scholar
• Daugherty T, Bonacini M. Therapy of hepatitis C in patients with HIV infection. Expert Rev Anti Infect Ther 2005;3(3):375-84
   PubMedGoogle Scholar
• Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010;5:61-9
   PubMed Web of Science ®Google Scholar
• Available form: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
   Google Scholar
• Sarda P, Sharma SK, Mohan A, Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009;129:64-7
   PubMed Web of Science ®Google Scholar
• Walker NF, Kliner M, Turner D, Hepatotoxicity and antituberculosis therapy: time to revise UK guidance? Thorax 2009;64:918
   PubMed Web of Science ®Google Scholar
• Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health 2009;14:1329-37
   PubMed Web of Science ®Google Scholar
• Gardiner P, Sarma DN, Low Dog T, The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf 2008;17:962-70
   PubMed Web of Science ®Google Scholar
• Suchard JR, Suchard MA, Steinfeldt JL, Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 2004;11:193-7
   PubMedGoogle Scholar
• Berman BM, Singh BK, Lao L, Physicians' attitudes toward complementary or alternative medicine: a regional survey. J Am Board Fam Pract 1995;8:361-6
   PubMedGoogle Scholar
• Fong TL, Klontz KC, Canas-Coto A, Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenetrol 2010;105(7):1561-6
   PubMed Web of Science ®Google Scholar
• Mazzanti G, Menniti-Ippolito F, Moro PA, Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009;65:331-41
   PubMed Web of Science ®Google Scholar
• Teschke R, Bahre R, Genthner A, Suspected black cohosh hepatotoxicity – challenges and pitfalls of causality assessment. Maturitas 2009;63:302-14
   PubMed Web of Science ®Google Scholar
• Cohen DE, Amanita FA, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C
   Web of Science ®Google Scholar
• Calderon RM, Cubeddu LX, Goldberg RB, Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 2010;85:349-56
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. Int J Pediatr Endocrinol 2009;2009:132041
   PubMedGoogle Scholar
• Khokhar O, Lewis JH. Hepatotoxicity from the agents used to treat inflammatory bowel disease. Digestive Diseases (Basel, Switzerland) 2010:28 [special issue Falk Symposium #172]
   Google Scholar
• Davern TJ, Chalasani N. Drug-induced liver injury in clinical trials: as rare as hens' teeth. Am J gastroenterol 2009;104:1159-61
   PubMed Web of Science ®Google Scholar
• Lee MS, Jung BH, Chung BC, Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Int J Toxicol 2009;28:392-404
   PubMed Web of Science ®Google Scholar
• Murayama H, Ikemoto M, Hamaoki M. Ornithine carbamyltransferase is a sensitive marker for alcohol-induced liver injury. Clin Chim Acta 2009;401:100-4
   PubMed Web of Science ®Google Scholar
• Harrill AH, Ross PK, Gatti DM, Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel. Toxicol Sci 2009;110:235-43
   PubMed Web of Science ®Google Scholar